Nephros (NEPH) Cash & Equivalents (2010 - 2026)

Nephros' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 1.54% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (down 1.54% YoY), while the FY2025 annual figure was $5.4 million, up 43.62% from the prior year.
• Cash & Equivalents was $4.0 million for Q1 2026 at Nephros, down from $5.4 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $5.4 million in Q1 2022 to a low of $2.5 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $4.2 million across 5 years, with a median of $4.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents plunged 49.52% in 2022, then soared 110.46% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $3.6 million in 2022, then gained by 18.52% to $4.3 million in 2023, then dropped by 12.7% to $3.8 million in 2024, then soared by 43.62% to $5.4 million in 2025, then dropped by 25.59% to $4.0 million in 2026.
• The last three Cash & Equivalents figures came in at $4.0 million (Q1 2026), $5.4 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.